Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback